KUALA LUMPUR: Strengthening research and development (R&D) infrastructure, especially in personalised medicine and digital healthcare, will empower the country to become a leader in global research and a hub for cutting-edge medical research.
Science, Technology and Innovation (Mosti) Minister Chang Lih Kang said investing in R&D drives economic growth by fostering innovation, creating high-tech jobs and enhancing global competitiveness.
With over 1,200 sponsored clinical trials hosted in 2023, Malaysia has established itself as a significant hub for clinical research in South-East Asia, he said.
“The outstanding work by RBS Research Grant recipients is pivotal to our national goals of advancing vaccine development, cancer research and public health.
“We are committed to building on this momentum to further strengthen our position in the global medical research community,” Chang said in his speech at the 2024 RBS Research Grant recipient announcement here yesterday, Bernama reported.
Also present were secretary-general to the ministry Datuk Dr Aminuddin Hassim and the Academy of Sciences Malaysia (ASM) president Datuk Dr Tengku Mohd Azzman Shariffadeen Tengku Ibrahim, who is also the Science, Technology and Innovation adviser to Prime Minister Datuk Seri Anwar Ibrahim.
